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696Objective: The development of a living, tissue-engineered vascular graft (TEVG) holds great promise for ad-
vancing the field of cardiovascular surgery. However, the ultimate source and time needed to procure these cells
remain problematic. Induced puripotent stem (iPS) cells have recently been developed and have the potential for
creating a pluripotent cell line from a patient’s own somatic cells. In the present study, we evaluated the use of
a sheet created from iPS cell–derived vascular cells as a potential source for the construction of TEVG.
Methods:Male mouse iPS cells were differentiated into embryoid bodies using the hanging-drop method. Cell
differentiation was confirmed by a decrease in the proportion of SSEA-1–positive cells over time using
fluorescence-activated cell sorting. The expression of endothelial cell and smooth muscle cell markers was de-
tected using real-time polymerase chain reaction (PCR). The differentiated iPS cell sheet was made using
temperature-responsive dishes and then seeded onto a biodegradable scaffold composed of polyglycolic
acid–poly-L-lactide and poly(L-lactide-co-ε-caprolactone) with a diameter of 0.8 mm. These scaffolds were im-
planted as interposition grafts in the inferior vena cava of female severe combined immunodeficiency/beige mice
(n¼ 15). Graft function was serially monitored using ultrasonography. The grafts were analyzed at 1, 4, and 10
weeks with histologic examination and immunohistochemistry. The behavior of seeded differentiated iPS cells
was tracked using Y-chromosome fluorescent in situ hybridization and SRY real-time PCR.
Results: All mice survived without thrombosis, aneurysm formation, graft rupture, or calcification. PCR eval-
uation of iPS cell sheets in vitro demonstrated increased expression of endothelial cell markers. Histologic eval-
uation of the grafts demonstrated endothelialization with von Willebrand factor and an inner layer with smooth
muscle actin- and calponin-positive cells at 10 weeks. The number of seeded differentiated iPS cells was found
to decrease over time using real-time PCR (42.2% at 1 week, 10.4% at 4 weeks, 9.8% at 10 weeks). A fraction
of the iPS cells were found to be Y-chromosome fluorescent positive at 1 week. No iPS cells were found to
co-localize with von Willebrand factor or smooth muscle actin-positive cells at 10 weeks.
Conclusions: Differentiated iPS cells offer an alternative cell source for constructing TEVG. Seeded iPS cells
exerted a paracrine effect to induce neotissue formation in the acute phase and were reduced in number by
apoptosis at later time points. Sheet seeding of our TEVG represents a viable mode of iPS cell delivery over
time. (J Thorac Cardiovasc Surg 2012;143:696-703)Surgeons and scientists have studied tissue engineering as
a method of creating blood vessel substitutes with the
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The Journal of Thoracic and Cardiovascular Surga tissue-engineered vascular graft (TEVG) with bone
marrow–derived mononuclear cells, differentiated smooth
muscle cells, or endothelial cells seeded onto a biodegradable
tubular scaffold has resulted in living vascular conduits with
properties that mimic those of a native vessel.2-5 We
translated this basic science research and performed the
first clinical trial evaluating the use of TEVGs in congenital
heart surgery.6 That pilot study demonstrated not only that
was it feasible to successfully implant TEVGs in humans,
but also that this technology was safe and efficacious.7,8
The ultimate source of the cells for seeding the TEVG,
however, remains problematic. In addition, little is known
about the mechanisms of seeded cell engraftment that un-
derlie the formation of vascular neotissue in vivo. To ex-
plore the cellular and molecular mechanisms essential for
neovessel formation, we developed a miniaturized version
of the tissue-engineered scaffold used in our clinical study
to enable TEVG implantation in a murine model.9 This
model showed that seeded bone marrow mononuclear cellsery c March 2012
Abbreviations and Acronyms
ESCs ¼ embryonic stem cells
iPS ¼ induced pluripotent stem
qRT-
PCR
¼ quantitative reverse-transcriptase
polymerase chain reaction
TEVG ¼ tissue-engineered vascular graft
Hibino et al Evolving Technology/Basic Scienceexerted a paracrine effect to induce neotissue formation and
disappeared in the acute phase soon after implantation. Al-
though bone marrow mononuclear cells were appropriate
for TEVG creation in a low-pressure venous model, a stron-
ger contribution of seeded cells seems to be required for ap-
propriate neovessel formation in high-pressure systems.
Embryonic stem cells (ESCs) have the potential to differ-
entiate into various cell types, and ESCs might provide
a source of cells for seeding a variety of tissue engineering
constructs.10 Because the clinical use of ESCs remains chal-
lenging owing to ethical and immunologic problems, in-
duced pluripotent stem (iPS) cells were developed by
inducing forced expression of certain stem cell–associated
genes in nonpluripotent cells.11
In the present study, we sought to determine whether
seeded iPS cells could differentiate into vascular neotissue
and contribute to neovessel formation in a murine model.E
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Culture and Differentiation of iPS Cells
iPS cells were purchased from RIKEN BioResource Center (Tokyo,
Japan)12 and maintained on mitomycin-treated embryonic feeders in Dul-
becco’s modified Eagle medium supplemented with 15% fetal bovine se-
rum (ThermoScientific Hyclone, Logan, Utah), 2 mM L-glutamine, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM B-mercaptoe-
thanol, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1000 U/mL
leukemia inhibitory factor. The cells were differentiated for 5 days as em-
bryoid bodies formed in hanging drops of embryonic stem cell medium
without leukemia inhibitory factor. At 5 days, the embryoid bodies were
dissociated into single cells with 0.25% trypsin for 5 minutes at 37C.13
Identification of Cell Differentiation
Cell differentiation was confirmed by a decrease over time in the pro-
portion of cells positive for SSEA-1 (R&D Systems, Minneapolis, Minn)
using fluorescence-activated cell sorting. The cells were acquired on a flu-
orescence-activated cell sorting Aria cell sorter (BD Biosciences, San Jose,
Calif), and the results were analyzed using DIVA software (BD
Bioscience). The expression of endothelial cell and smooth muscle cell
markers was detected using real-time quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR). RNA extraction from the explanted
scaffold was performed with an RNeasy Mini Kit (Qiagen, Valencia, Calif)
according to the manufacturer’s protocol. Predesigned and validated gene-
specific TaqMan Gene Expression Assays from Applied Biosystems
(Life Technologies, Foster City, Calif) were used in duplicate for qRT-
PCR according to the manufacturer’s protocol. The genes of interest for
analysis were calponin, platelet-endothelial cell adhesion molecule-1, vas-
cular endothelial growth factor, and E-cadherin. qRT-PCR was performed
in 96-well reaction plates using the iCycler iQ Real-Time PCR DetectionThe Journal of Thoracic and CaSystem (Bio-Rad, Hercules, Calif). Each qRT-PCR reaction consisted of
the following steps: 2 minutes of uracil-N-glycosylase incubation at 50C
to remove possible amplicon contamination, followed by 10 minutes at
95C to activate the polymerase, and 40 cycles of 15 seconds denaturing
at 95C, and 1minute at 60Cof extension and annealing. The datawere col-
lected at the end of each elongation step and analyzed with the iCycler iQ
Real Time Detection System Software (Bio-Rad). Hypoxanthine-guanine
phosphoribosyltransferase was used as an endogenous control.
Creation of iPS Cell Sheet-Seeded TEVG
iPS Cell sheet fabrication. The differentiated iPS cell sheet was
made using temperature-responsive dishes (Cellseed, Tokyo, Japan) and
then seeded onto a biodegradable scaffold composed of polyglycolic
acid–poly-L-lactide and poly(L-lactide-co-ε-caprolactone) with a diameter
of 0.8 mm.
Scaffold fabrication. The scaffolds were constructed from a nonwo-
ven polyglycolic acid mesh (Concordia Fibers, Coventry, RI) and a copoly-
mer sealant solution of poly-L-lactide and poly(L-lactide-co-ε-caprolactone
using the dual cylinder chamber molding system, as previously described.9
TEVG implantation. TEVG implantations were performed using
microsurgical technique. The scaffolds were inserted into the infrarenal in-
ferior vena cavas of 3- to 4-month-old, female severe combined immuno-
deficiency/beige mice (Jackson Laboratories, Bar Harbor, Maine), as
previously described.9 A total of 15 mice were implanted with TEVG.
All animal experiments were done in accordance with the institutional
guidelines for the use and care of animals, and the institutional review
board approved the experimental procedures described.
Ultrasonography
Serial ultrasound scans (VevoVisualsonics, Toronto, Canada) were used
for graft surveillance in both the seeded and the unseeded groups. Before
ultrasonography, the mice were anesthetized with 1.5% inhaled isoflurane.
Histologic Analysis
The grafts were analyzed at 1, 4, and 10 weeks with histologic exami-
nation and immunohistochemistry.
Histologic examination. The explanted grafts were pressure fixed
in 10% formalin overnight and then embedded in paraffin or glycolmetha-
crylate using previously published methods.9 The sections were stained
with hematoxylin and eosin.
Immunohistochemistry. The primary antibodies included mouse–
anti-human smoothmuscle actin (Dako, Carpinteria, Calif) and rabbit–anti-
human von Willebrand factor (Dako), both of which have crossreactivity
with mouse. Antibody binding was detected using a goat–anti-rabbit
IgG-Alexa Fluor 488 or a goat–anti-mouse IgG-Alexa Fluor 488 (Invitro-
gen, Carlsbad, Calif).
iPS Cell Quantification Using Real-Time qRT-PCR
Explanted tissue grafts were frozen in OCT compound and each sec-
tioned into 40 sections of 10 mmusing Cryocut 1800 (Leica, Buffalo Grove,
Ill). Excess OCT compound was removed by centrifugation in water. After
tissue digestion, DNAwas isolated from samples using the DNeasy Blood
and Tissue Kit (Qiagen) according to the manufacturer’s instructions. Val-
idated gene-specific TaqMan Gene Expression Assays from Applied Bio-
system (Foster City, Calif) predesigned to amplify the SRY gene were
used in duplicate for qRT- PCR according to the manufacturer’s protocol.
DNA amplification and quantification was performed using the iCycler iQ
Real-Time PCR Detection System (Bio-Rad). Each qRT-PCR reaction con-
sisted of the following steps: 2minutes of uracil-N-glycosylase incubation at
50C to remove possible amplicon contamination, followed by 10minutes at
95C to activate the polymerase, and 40 cycles of 15 seconds denaturing at
95C and 1 minute at 60C of extension and annealing. The data wererdiovascular Surgery c Volume 143, Number 3 697
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Real Time Detection System Software (Bio-Rad). The percentage of Y
chromosome–positive cells remaining on the graft were then determined us-
ingquantificationofSRYDNAcontent, as previously described,14 takingad-
vantage of the male iPS cell–seeded TEVGs having been implanted into
female mice.
Y-chromosome fluorescent in situ hybridization/termi-
nal deoxynucleotidyl transferase dUTP nick end label-
ing staining. Fluorescent in situ hybridization was performed on
paraffin sections using digoxigenin-labeled mouse Y-chromosome probe
detected with a Rhodamine-conjugated antibody to digoxigenin (Roche
Diagnostics, Mannheim, Germany), as previously described.15,16 Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
was performed using the DeadEnd Fluorometric TUNEL System kit
according to the manufacturer’s instructions (Promega, Madison, WI).
Combined fluorescent in situ hybridization/TUNEL was performed by
completing the TUNEL protocol, starting with the equilibration buffer
step after anti-digoxigenin hybridization. Image acquisition was performed
using a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar,
Germany).
Statistical Analysis
Statistical differences were measured using Student’s t test or analysis
of variance. P<.05 was considered statistically significant.RESULTS
The differentiation of iPS cells in vitro was confirmed us-
ing cell surface markers. Fluorescence-activated cell sorting
analysis of the iPS cells demonstrated that the ratio of undif-
ferentiated SSEA-1–positive cells decreased over time after
switching to differentiation medium (day 0, 81.0%; day 10,
28.7%; day 20, 4.3%; Figure 1, A). Concurrently, these dif-
ferentiated cells expressed endothelial cell markers, includ-
ing vascular endothelial growth factor, platelet-endothelial
cell adhesion molecule-1, and E-cadherin, and the smooth
muscle cell marker calponin (Figure 1, B).
Next, to identify the proper conditions for cell attach-
ment to the scaffold, 5 million differentiated iPS cells
were seeded onto the graft by manual pipetting. The num-
ber of attached cells and the seeding efficiency were then
measured over time. No significant difference was foundFIGURE 1. Confirmation of differentiation of induced pluripotent stem (iP
fluorescence-activated cell sorting analysis decreased over time after changing
endothelial growth factor [VEGF], platelet-endothelial cell adhesion molecule-
differentiated iPS cells.
698 The Journal of Thoracic and Cardiovascular Surgin the attached cell number and seeding efficiency at
1, 3, and 7 days (seeding efficiency: 1 day, 6.5% 
0.8%; 3 days, 7.6%  2.5%; 7 days, 8.6%  2.5%;
Figure 2). Because the seeding efficiency was very low, re-
gardless of the incubation period, we developed a new
seeding method using a sheet of differentiated iPS cells
wrapped around the scaffold to seed cells more effectively.
This new method using an iPS cell sheet significantly im-
proved the seeding efficiency compared with traditional
pipette seeding (sheet, 86.5%  11.8%; traditional,
4.9%  1.5%; Figure 3).
After implantation of this differentiated iPS cell sheet-
seeded scaffold, all mice survived without thrombosis,
aneurysm formation, graft rupture, or calcification. Ultra-
sonography showed patent grafts at 10 weeks (Figure 4,
E). Histologic evaluation of the grafts demonstrated endo-
thelialization with von Willebrand factor and an inner
layer with smooth muscle actin–positive cells at 10 weeks
(Figure 4, C, D). Because the male iPS cell–seeded graft
was implanted into female mice, the seeded cells were
identified using Y-chromosome fluorescent in situ hybrid-
ization. Some seeded cells remained on the outer layer
of the graft at 1 week after implantation. At 4 weeks,
very small numbers of seeded cells were found. The num-
ber of seeded differentiated iPS cells quantified by real-
time PCR decreased dramatically over time (1 week,
42.2%; 4 weeks, 10.4%; 10 weeks, 9.8%; Figure 5). A
fraction of the iPS cells was found to be TUNEL positive
at 1 week (Figure 6). No iPS cells were co-localized with
von Willebrand factor or smooth muscle actin–positive
cells at 10 weeks. We also found teratoma formation in 1
of 5 mice at 10 weeks.
DISCUSSION
In the present study, we demonstrated the feasibility of
using a differentiated iPS cell sheet as an alternative cell
source for TEVG creation. Most of the seeded iPS cells dis-
appeared as a result of apoptosis at later points, suggestingS) cells in vitro. A, Ratio of undifferentiated SSEA-1–positive cells by
to differentiation medium. B, Expression of endothelial markers (vascular
1 [PECAM], and E-cadherin) and smooth muscle cell marker (calponin) in
ery c March 2012
FIGURE 2. Attached cell number and seeding efficiency of differentiated induced pluripotent stem (iPS) cells seeded onto the scaffold. No significant
difference was found for any incubation period.
Hibino et al Evolving Technology/Basic Sciencethat seeded iPS cells exerted a paracrine effect to induce
neotissue formation in the acute phase.
Cells are 1 of the key factors involved in vascular regen-
eration, and various cell types have been used for vascular
tissue engineering. Stem cells or progenitor cells can differ-
entiate into vascular cells that form new vessels or tissues.
Mesenchymal stem cells17 and endothelial progenitor
cells18 reside in the bone marrow and have been studied
most for their vascular regeneration potential. Bone
marrow-derived stem cells have undergone the most trans-
lational and human studies of all stem cell approaches.
The clinical trials performed to date show little increased
risk associated with their therapeutic use in humans.19,20FIGURE 3. Differentiated induced pluripotent stem (iPS) cell sheet seeded tis
entiated iPS cells. B, The scaffold was wrapped with this cell sheet for seeding
improved seeding efficiency compared with traditional pipette seeding. D, Dif
vena cava.
The Journal of Thoracic and CaHowever, bone marrow–derived stem cell therapy has lim-
itations. The typical surface markers used to isolate these
stem cells result in a mixed population of cells that have
not been completely characterized.21-24 In addition, in the
patients who most need stem cell therapy, these cells are
rare, have limited replicative capacity, and are often
dysfunctional, especially in patients who have the
conditions typically associated with vascular disease, such
as older age and diabetes mellitus, which impair
angiogenic functionality.21,25
Our previous studies have demonstrated the feasibility of
creating TEVGs by seeding bone marrow mononuclear
cells onto biodegradable tubular scaffolds.2,3 These cellssue-engineered vascular graft (TEVG). A, Cell sheet creation from differ-
. C, New seeding method using a differentiated iPS cell sheet significantly
ferentiated iPS cell sheet seeded TEVG was implanted in mouse inferior
rdiovascular Surgery c Volume 143, Number 3 699
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FIGURE 4. Histologic examination of tissue-engineered vascular graft (TEVG). A, Seeded induced pluripotent stem (iPS) cells were identified as Y chro-
mosome fluorescent in situ hybridization–positive cells (red) at 1 week after implantation (blue indicates DAPI). B, At 4 weeks, very small numbers of
seeded cells were found. At 10 weeks, (C) endothelialization was present with von Willebrand factor (green) and (D) an inner layer with smooth muscle
actin (green)-positive cells at 10 weeks. However, no Y chromosome fluorescent in situ hybridization–positive seeded iPS cells (red) were seen. E, Hema-
toxylin and eosin staining and (F) ultrasonography showed patent graft at 10 weeks.
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effect to facilitate neotissue creation.26 In addition, we
have shown that it takes 10 weeks for complete neovessel
formation with endothelialization and smooth muscle layer
creation. Compared with bone marrow–derived stem cells,
ESCs have the advantage of pluripotentiality and greaterFIGURE 5. Quantification of seeded differentiated induced pluripotent stem (iP
reaction (PCR) using probe for SRY. Number of seeded iPS cells decreased dr
700 The Journal of Thoracic and Cardiovascular Surgproliferative capacity, suggesting they might be a useful
source for cell seeding, but the clinical use of ESCs remains
conflicted by ethical debate and immunologic barriers. As
an alternative to ESCs, iPS cells are generated by inducing
forced expression of certain stem cell–associated genes in
nonpluripotent cells.11,27,28 iPS cells are similar to ESCsS) cells using real-time quantitative reverse transcriptase polymerase chain
amatically over time.
ery c March 2012
FIGURE 6. Therewas mixture of surviving (yellow arrows) and apoptotic
(white arrows) seeded induced pluripotent stem (iPS) cells at 1 week after
graft implantation (green indicates terminal deoxynucleotidyl transferase
dUTP nick end labeling positive; red indicates SRY fluorescent in situ hy-
bridization positive; and blue indicates DAPI).
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donor-specific pluripotent cells. Recent reports have shown
that murine iPS cells can be differentiated into cardiovascu-
lar cells needed to repair heart and blood vessels and might
represent a valuable cell source for vascular regenera-
tion.29,30 Therefore, we investigated the application of
stem cell technology with the idea of creating a patient’s
own stem cells to promote earlier and better vascular
neotissue formation.
Seeding methods for the delivery of iPS cells are diverse,
and no method has been clearly shown to be superior in ei-
ther promoting seeding efficiency or improving long-term
graft function.31 To date, the most common method used
in the construction of TEVGs is static seeding, in which
a concentrated cell suspension is passively introduced
onto a scaffold. This technique has several limitations that
result in low efficiency seeding and minimal cell penetra-
tion of scaffold walls. As we demonstrated in the present
study, the average seeding efficiency is around 10%.
Yang and colleagues,32 Sekine and colleagues,33 and Shi-
mizu and colleagues34 developed a novel cell sheet system
to engineer a graft that contracts in 3 dimensions. The tech-
nique to obtain a stable cell sheet was the use of
temperature-responsive culture surfaces. A stable cell sheet
of single-cell thickness can be harvested without losing the
intercellular connections and then can be transferred to
a second and third cell sheet. To increase the delivery ofThe Journal of Thoracic and CaiPS cells with our TEVG, we applied this cell sheet technol-
ogy for differentiated iPS cells, and the seeding efficiency
was found to be significantly improved.
Although the sheet seeding method led to a dramatic im-
provement in seeding efficiency, our results in vivo suggested
that seeded iPS cells disappeared in the acute phase by apo-
ptosis. Although the cell number remaining on the graft after
implantation was greater than in our previous study,26 no en-
graftment of seeded cells was seen in our neovessels at 10
weeks. Some groups, however, have reported that seeded
iPS cells can engraft with tissue in other models. In a study
of rat arterial TEVGs fabricated with biodegradable tubular
scaffolds and seeded with muscle-derived stem cells, the en-
graftment of seededmuscle-derived stem cells in the vascular
tissue was identified by the direct comparison between the
histologic findings and LacZ-positive seeded cell images.35
In amurinemodel of ischemicmyocardium, transplanted en-
dothelial cells differentiated from ESCs were tracked using
bioluminescence imaging, which showed the persistence of
the cells up to 8 weeks later. Echocardiography in that study
revealed improved systolic function in hearts injected with
ESC-ECs compared with vehicle.36 However, other groups
have reported findings consistent with the results of our
study. In a study of transplantation of human ESC-derived
cardiomyocytes into ischemic murine myocardium, im-
planted cells died soon after transplantation into the infarcted
heart. This problemwas also found in other cell therapies for
diabetes,37,38 Parkinson’s disease,39,40 and muscular
dystrophy.41,42 Because the death of these transplanted
cells was multifactorial in origin, varied and complex
interventions were required for the engraftment of cells in
tissue. A cocktail of pro-survival factors, including matrigel
and inhibitors of apoptosis, was proposed for targeting the
key components of potential cell death pathways.43Although
the fate of seeded cells is controversial, the additional eluci-
dation of pathways that cause iPS cell death would be an im-
portant next step to better understand and enhance the role of
seeded iPS cells in the creation of improved TEVGs.
The heterogeneity inherent to the epigenetics and gene
expression profiles of pluripotent cells raises concern for
pleiotropic outcomes such as teratoma formation.44 Our
study showed that teratomas formed in 25% of the grafts.
To prevent the formation of teratomas, additional purifica-
tion of differentiated iPS cells is required. Isolation using
immunomagnetic beads or culture with growth factors
such as vascular endothelial growth factor and platelet-
derived growth factor-BB are possible methods for im-
provement in purification.45,46 However, no method to
properly direct this differentiation has yet been mastered.
Studies have demonstrated that no growth factor causes
differentiation along a single cell line, and, in contrast,
differentiation has been shown to be spontaneous.47,48
In conclusion, differentiated iPS cells provide an alterna-
tive and attractive cell source for constructing TEVGs usingrdiovascular Surgery c Volume 143, Number 3 701
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that the number of seeded iPS cells decreased over time
as a result of apoptosis in the early phase, seeded iPS cells
could work as a paracrine effect to induce neotissue forma-
tion in the acute phase. However, additional study such as
cytokine arrays or microarrays is required to show the exact
mechanism of paracrine effect. Some possibility of tera-
toma formation in the present differentiation method re-
mains, representing a drawback for clinical applications
of this approach. Additional study of the inhibition of apo-
ptosis of seeded cells and the improvement in iPS cell puri-
fication procedures will enable the design and creation of
the next generation of TEVGs.
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Dr John E. Mayer, Jr. (Boston, Mass). Congratulations on
a very interesting study and on successfully overcoming the tech-
nical challenges of both the cell seeding problem and the implant
of these tiny vascular grafts. Thank you for sending the manuscript
and figures in advance.
I have a couple of specific questions and then a more general
one. First of all, what was the thickness of the cell layers that
were wrapped around the scaffolds? Do you think that nutrient dif-
fusion limitations contributed to the apoptosis and the falling num-
bers of seeded cells in the grafts?
Dr Hibino. Thank you so much for your comment, Dr Mayer.
The thickness of the cell sheet is about 100 mm. Dr Okano’s
group, which developed this cell sheet technique, showed electri-
cal coupling of double-layered neonatal rat cardiomyocyte sheets
in vitro. They also reported 3-dimensinoal myocardial sheet tissueThe Journal of Thoracic and Caconstruction using 4-layer sheets in vivo. Based on these studies,
our iPS sheet seems to have sufficient nutrient support by simple
diffusion.
Dr Mayer. The second question is, do you know whether the
cells that you have wrapped around your scaffold actually pene-
trate into the luminal surface before implant? If not, then you
just had bare scaffold facing the bloodstream. How did you prevent
thrombosis?
DrHibino.Wedid not examine the exact luminal penetration of
the iPS cells, but the iPS cells should attach each other very
strongly because other previous studies demonstrated there is
a gap junction communication between the cells by the expression
of connexin 43 in various cell types. In addition, our previous study
using bone marrow mononuclear cell-seeded grafts demonstrated
that our SCID/beige mouse model showed almost 100% patency
even in the venous circulation because of the deficiency of the im-
mune function and platelet function.
Dr Mayer. So did you use heparin or any other anticoagulants
around the time of implant?
Dr Hibino. No, we did not use any anticoagulant.
Dr Mayer. Finally, the last questions, and the big questions re-
ally, are, first, how can we control the teratoma formation, and sec-
ond, can you speculate on the specific paracrine effects that seem
to be active here as opposed to there just being implantation cell
effects?
Dr Hibino. Regarding the prevention of teratoma formation,
enhanced purification of differentiated iPS cells would be the
most important factor. So our collaborator at the Yale stem cell
center is developing an improved method for this problem. They
insert green fluorescent protein with a specific promoter gene to in-
duce the differentiation to the vascular cell lineage and are then
able to select green fluorescent protein-positive cells later.
Regarding the possible paracrine mechanism for neovessel for-
mation, we are looking for the effect of specific cytokines such as
transforming growth factor-beta, fibroblast growth factor, or
monocyte chemotactic protein-1 using a transgenic mouse model.
Additional purification of differentiated iPS cells and an under-
standing of the combination of specific cytokines would be
a very important factor in the future.rdiovascular Surgery c Volume 143, Number 3 703
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